Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction (original) (raw)

Jean-Claude Tardif (1, 2) , Simon Kouz (3) , David Waters (4) , Olivier Bertrand (5) , Rafael Diaz (6) , Aldo Maggioni (7) , Fausto Pinto (8) , Reda Ibrahim (9) , Habib Gamra (10, 10) , Ghassan Kiwan (11) , Colin Berry (12, 13) , José López-Sendón (14) , Petr Ostadal (15) , Wolfgang Koenig (16, 17) , Denis Angoulvant (18, 19, 20, 21) , Jean Gregoire (22) , Marc-André Lavoie (22) , Marie-Pierre Dubé (22) , David Rhainds (22) , Mylène Provencher (23) , Lucie Blondeau (23) , Andreas Orfanos (23) , Philippe L'Allier (22) , Marie-Claude Guertin (24, 23) , François Roubille (25, 26)

1 MHICC - Montreal Heart Institute Coordinating Centre
2 Montreal Heart Institute, Montreal, Canada
3 ULaval - Université Laval [Québec]
4 UC San Francisco - University of California [San Francisco]
5 Institut de Cardiologie et Pneumologie de Québec, Quebec City
6 ECLAEstudios Clínicos Latino América & Instituto Cardiovascular de Rosario), Rosario, Argentina
7 ANMCO Research Center - Research Center [Associazione Nazionale Medici Cardiologi Ospedalieri]
8 Faculdade de Medicina [Lisboa]
9 Montrea l Heart Institute, Université de Montréal, Montreal, Canada
10 HFB - CHU Fattouma Bourguiba [Monastir]
11 Bellevue Medical Center, Beirut, Lebanon
12 University of Glasgow
13 BHF GCRC - British Heart Foundation Glasgow Cardiovascular Research Centre
14 Cardiology department Hospital Universitario La Paz. UAM. IdiPaz. CIBER-CV, Madrid, Spain
15 Department of Cardiology Cardiovascular Center, NaHomolce Hospital, Prague, Czech Republic;
16 Department of Internal Medicine II – Cardiology
17 München, Technische Universität München, German Research Center for Cardiovascular Disease (DZHK), Partner site Munich Heart Alliance, Institute of Epidemiology and Medical Biometry, University of Ulm, Munich, Germany
18 T2i - Transplantation, Immunologie, Inflammation [Tours]
19 Centre Hospitalier Universitaire (CHU) de Tours and Équipe d'Accueil 4245 Transplantation Immunité Inflammation Loire Valley Cardiovascular Collaboration, Tours University, Tours
20 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
21 UT - Université de Tours
22 Montreal Heart Institute - Institut de Cardiologie de Montréal
23 MHICC - Montreal Health Innovations Coordinating Center [Montreal Heart Institute]
24 Montreal Health Innovation Coordination Center
25 PhyMedExp - Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046]
26 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]

Résumé

Experimental and clinical evidence support the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis.

Domaines

Connectez-vous pour contacter le contributeur

https://hal.science/hal-02368804

Soumis le : mardi 23 juin 2020-08:41:02

Dernière modification le : jeudi 18 décembre 2025-08:52:04

Archivage à long terme le : jeudi 24 septembre 2020-15:09:58

Dates et versions

hal-02368804 , version 1 (23-06-2020)

Licence

Identifiants

Citer

Jean-Claude Tardif, Simon Kouz, David Waters, Olivier Bertrand, Rafael Diaz, et al.. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine, 2019, ⟨10.1056/NEJMoa1912388⟩. ⟨hal-02368804⟩

3911 Consultations

411 Téléchargements

Altmetric